Last reviewed · How we verify
Placebo ZNS
Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade.
Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade. Used for Adjunctive therapy for partial seizures in epilepsy, Infantile spasms (West syndrome).
At a glance
| Generic name | Placebo ZNS |
|---|---|
| Also known as | Placebo |
| Sponsor | Impax Laboratories, LLC |
| Drug class | Anticonvulsant / Antiepileptic agent |
| Target | Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Zonisamide inhibits voltage-gated sodium and T-type calcium channels, reducing repetitive neuronal firing and stabilizing neuronal membranes. It also has carbonic anhydrase inhibitory activity and may enhance GABAergic neurotransmission, contributing to its anticonvulsant effects.
Approved indications
- Adjunctive therapy for partial seizures in epilepsy
- Infantile spasms (West syndrome)
Common side effects
- Somnolence
- Ataxia
- Dizziness
- Anorexia / weight loss
- Cognitive impairment
- Nephrolithiasis
- Hyperthermia (especially in children)
Key clinical trials
- Noise-Induced Hearing Loss-Acute Exposure Treatment (UA) (PHASE2)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (PHASE2)
- Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study (NA)
- Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE (PHASE3)
- A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo ZNS CI brief — competitive landscape report
- Placebo ZNS updates RSS · CI watch RSS
- Impax Laboratories, LLC portfolio CI